167 related articles for article (PubMed ID: 19098003)
1. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.
Tvorogov D; Sundvall M; Kurppa K; Hollmén M; Repo S; Johnson MS; Elenius K
J Biol Chem; 2009 Feb; 284(9):5582-91. PubMed ID: 19098003
[TBL] [Abstract][Full Text] [Related]
2. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
3. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
[TBL] [Abstract][Full Text] [Related]
4. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
[TBL] [Abstract][Full Text] [Related]
5. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological postconditioning with Neuregulin-1 mimics the cardioprotective effects of ischaemic postconditioning via ErbB4-dependent activation of reperfusion injury salvage kinase pathway.
Wang F; Wang H; Liu X; Yu H; Zuo B; Song Z; Wang N; Huang W; Wang G
Mol Med; 2018 Jul; 24(1):39. PubMed ID: 30134819
[TBL] [Abstract][Full Text] [Related]
7. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.
Li S; Ma YM; Zheng PS; Zhang P
J Exp Clin Cancer Res; 2018 Apr; 37(1):80. PubMed ID: 29636108
[TBL] [Abstract][Full Text] [Related]
8. ErbB4 signals Neuregulin1-stimulated cell proliferation and c-fos gene expression through phosphorylation of serum response factor by mitogen-activated protein kinase cascade.
Eto K; Hommyo A; Yonemitsu R; Abe S
Mol Cell Biochem; 2010 Jun; 339(1-2):119-25. PubMed ID: 20066477
[TBL] [Abstract][Full Text] [Related]
9. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
10. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
Gordon-Thomson C; Jones J; Mason RS; Moore GP
Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
[TBL] [Abstract][Full Text] [Related]
11. Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart.
Chung KY; Walker JW
Mol Pharmacol; 2007 Jun; 71(6):1494-502. PubMed ID: 17332141
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
13. A new isoform of interleukin-3 receptor {alpha} with novel differentiation activity and high affinity binding mode.
Chen J; Olsen J; Ford S; Mirza S; Walker A; Murphy JM; Young IG
J Biol Chem; 2009 Feb; 284(9):5763-73. PubMed ID: 19109256
[TBL] [Abstract][Full Text] [Related]
14. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line.
Pontillo CA; García MA; Peña D; Cocca C; Chiappini F; Alvarez L; Kleiman de Pisarev D; Randi AS
Toxicol Sci; 2011 Apr; 120(2):284-96. PubMed ID: 21205633
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
16. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
17. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kharmate G; Rajput PS; Watt HL; Somvanshi RK; Chaudhari N; Qiu X; Kumar U
Biochim Biophys Acta; 2011 Jun; 1813(6):1172-89. PubMed ID: 21419811
[TBL] [Abstract][Full Text] [Related]
18. EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.
Kapoor GS; Christie A; O'Rourke DM
Cancer Biol Ther; 2007 Apr; 6(4):571-9. PubMed ID: 17457042
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.
Pitfield SE; Bryant I; Penington DJ; Park G; Riese DJ
Oncol Res; 2006; 16(4):179-93. PubMed ID: 17120616
[TBL] [Abstract][Full Text] [Related]
20. Akt-mediated survival of oligodendrocytes induced by neuregulins.
Flores AI; Mallon BS; Matsui T; Ogawa W; Rosenzweig A; Okamoto T; Macklin WB
J Neurosci; 2000 Oct; 20(20):7622-30. PubMed ID: 11027222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
